Brief: Mirum Enrolls First Patient in Phase 2 Fragile X Study of MRM-3379
01/12/2025 13:18
Dec 1 (Reuters) - Mirum Pharmaceuticals Inc MIRM.O: MIRUM PHARMACEUTICALS ANNOUNCES FIRST PATIENT ENROLLED IN THE BLOOM PHASE 2 CLINICAL STUDY EVALUATING MRM-3379 IN FRAGILE X SYNDROME MIRUM PHARMACEUTICALS INC - TOP-LINE DATA FROM BLOOM PHASE 2 STUDY EXPECTED IN 2027 Source text: ID:nBw7YTf0ra Further company coverage: MIRM.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mirum Pharmaceuticals
See all newsMirum Pharmaceuticals Q3 net product sales surge, outlook raised
Brief: Mirum Pharmaceuticals Announces Positive Results From Cohort 2 Of The Pivotal Progress Study Of Atebrioz™ (Zilurgisertib) In Pediatric Patients Aged 6 To <12 Years With Fibrodysplasia Ossificans Progressiva
Mirum climbs on positive late-stage trial results for liver disease drug
US STOCKS ON THE MOVE-Mirum Pharmaceuticals, Meta, Boeing
U.S. STOCKS ON THE MOVE-Royal Caribbean Cruises, SpaceX